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Abstract
Background: With the availability of infliximab, nowadays recurrent Crohn's disease, defined as
disease refractory to immunomodulatory agents that has been treated with steroids, is generally
treated with infliximab. Infliximab is an effective but expensive treatment and once started it is
unclear when therapy can be discontinued. Surgical resection has been the golden standard in
recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized
by a quick symptom reduction.
The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection
in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and
costs.
Methods/design: The study is designed as a multicenter randomized clinical trial including patients
with Crohn's disease located in the terminal ileum that require infliximab treatment following
recent consensus statements on inflammatory bowel disease treatment: moderate to severe
disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy.
Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic
resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay,
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early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5
on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power
of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation
will be performed by assessing the marginal direct medical, non-medical and time costs and the
costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a
cost-utility ratio will be calculated. Patients will be included from December 2007.
Discussion: The LIR!C-trial is a randomized multicenter trial that will provide evidence whether
infliximab treatment or surgery is the best treatment for recurrent distal ileitis in Crohn's disease.
Trial registration: Nederlands Trial Register NTR1150
Background
Crohn's disease is an inflammatory bowel disease that
affects the entire gut, but mostly the terminal ileum of the
small bowel is involved. Due to the chronic inflammation
the affected bowel segment is scarred and may become
stenotic. Although medical treatment aims to reduce the
inflammation, many patients eventually will have surgery
because of obstructive complaints [1].
Primary medical treatment is still considered the preferred
treatment because of the potential morbidity associated
with surgery. Furthermore, medical treatment might avert
surgery. Medical therapy consists of remission induction
by a short course of steroids most often followed by main-
tenance therapy with immunomodulating agents. Recur-
rence of disease activity is primarily treated with steroids.
Frequent disease exacerbations and steroid dependency
are an indication for treatment with infliximab. Inflixi-
mab is a chimeric anti-TNF monoclonal antibody against
tumor necrosis factor, an important proinflammatory
cytokine in Crohn's disease. Treatment with this biologi-
cal is effective in inducing and maintaining response and
remission in patients with moderate to severe Crohn's dis-
ease.
Infliximab therapy once initiated is best continued at 8
weeks intervals, although interval therapy is often used to
reduce costs and to avoid the risks of long-term immune
suppression. Major drawbacks of medical therapy are
long-term use of medication with associated impairment
of quality of life, morbidity and high costs. Furthermore,
infliximab treatment is an open-ended medical treatment:
it is unclear for how long therapy should be continued.
Interrupting the treatment is undesirable since it is associ-
ated with loss of response due to anti-infliximab antibody
formation [2-4]. It remains unclear in how many patients
with recurrent Crohn's disease surgery can eventually be
avoided [1] Thus, patients with recurrent Crohn's disease
encompass a heterogeneous group of patients some of
which will respond to (long-term) medical treatment
whereas in others surgery cannot be averted by medical
treatment.
It is well established that an ileocolic resection is an effec-
tive and low morbidity operation resulting in a quick
relieve of complaints and fast restoration of quality of life.
Most frequent complications requiring reoperation are
anastomotic dehiscence and intra-abdominal abscess. In
several publications analyzing safety of laparoscopic ileo-
colic resection, the percentage of complications requiring
reoperation varied from 0 to 7.6% [5]. After ileocolic
resection, medication can be stopped or limited to pro-
phylactic medication when indicated [6]. The length of
loss of small bowel is generally limited and averages 20–
25 cm in patients who had surgery for obstructive symp-
toms refractory to medical treatment. Long-term surgical
recurrence occurs in 20–25% over an 8–9 years period in
patients refractory to medication [7,8].
Patients are generally young and in the middle of building
their socioeconomic life. Disease activity with its associ-
ated complaints and long-term therapy have a pro-
nounced effect on quality of life characterized by sick
leave and non-attendance of social activities [9,10].
Patients that have a clinical recurrence after medical treat-
ment can be considered as patients having a more severe
type of the disease. To date consensus statements offer
either treatment with infliximab or surgical resection in
limited disease, because no comparative studies on the
two alternatives exist. It can be hypothesized that surgery
may avoid long-term or ineffective medical treatment
improving quality of life and reducing costs. With the
implementation of the laparoscopic approach, morbidity
and overall costs are further reduced, and body image and
cosmesis are maintained [5,11-15]. For these reasons time
has come to compare laparoscopic ileocolic resection with
infliximab treatment in terms of quality of life, sick leave
and costs.
Methods/design
Study objectives
To compare, in a prospective randomized setting, the
short-term and medium-term effectiveness and costs of
ileocolic resection versus infliximab therapy in patientsBMC Surgery 2008, 8:15 http://www.biomedcentral.com/1471-2482/8/15
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with recurrent Crohn's disease of the distal ileum. Two
research questions can be defined:
1. How does infliximab treatment of patients with recur-
rent Crohn's disease of the distal ileum compare with
laparoscopic ileocolic resection in terms of quality of life,
hospital stay, morbidity, sick leave and surgical (re)inter-
ventions?
2. What are the 12 months cumulative total costs of inflix-
imab treatment versus laparoscopic ileocolic resection in
patients with recurrent Crohn's disease of the distal
ileum?
Study design
The LIR!C-study is a randomized multicenter trial with
participation of at least five academic and 20 regional hos-
pitals. Patients presenting with recurrent or resistant
Crohn's disease of the distal ileum will be counseled and
asked for informed consent if the inclusion and exclusion
criteria are met. Randomization will take place after
informed consent has been obtained. Patients will be ran-
domized to either a laparoscopic ileocolic resection or to
treatment with infliximab (see Figure 1).
Randomization is performed by an Internet randomiza-
tion module prepared by the Department of Clinical
Research and Data management. Biased-coin randomiza-
tion is used and the randomization is stratified for the ran-
domizing centers and the presence or absence of peri-anal
fistulas.
Primary and secondary endpoints
The primary endpoints of the LIR!C trial are the disease-
specific quality of life as measured by the IBDQ [16,17]
and the costs per QALY.
Secondary outcome parameters are general quality of life,
as measured by the SF-36 [18] and EQ 5D [19,20] ques-
tionnaires; number of days on sick leave; morbidity (due
LIR!C-trial flowchart Figure 1
LIR!C-trial flowchart.
Patients with Crohn’s disease located in the terminal ileum 
that fail to respond to steroid or immunomodulatory therapy.
Decline to participate
Randomization after informed 
consent (N=130) 
Laparoscopic ileocolic resection (N=65) 
•Remission-induction with prednisolone: 1 week 40 
mg/day, 1 week 30 mg/day, 1 week 20 mg/day, 1 
week 10 mg/day 
•Laparoscopic ileocolic resection 
Infliximab (N=65) 
•Remission induction: 3 infusions at week 0, 2 and 6 
in a dose of 5 mg/kg in combination with 
azathioprine / 6 mercaptopurine / methotrexaat 
•Maintenance therapy: 5 mg/kg every 8 weeks 
Follow-up for 12 months 
Analysis on intention-to-treat basis:  
quality of life and costs  BMC Surgery 2008, 8:15 http://www.biomedcentral.com/1471-2482/8/15
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to either surgery or medical treatment), total in and out
hospital medical and non-medical costs and body image
and cosmesis as measured by the body image question-
naire (BIQ) [13].
Study population
The study population consists of patients with recurrent
or resistant Crohn's disease of the distal ileum, not
responding to immunomodulating therapy.
Inclusion criteria are: age in between 18 and 80 years,
recurrent Crohn's disease of the distal ileum, a completed
IBDQ, SF-36 and EQ-5D and BIQ before randomization,
informed consent.
Exclusion criteria are: prior ileocolic resection for Crohn's
disease, obstructive Crohn's disease of the distal ileum
requiring surgery, diseased small bowel segment longer
than 40 cm, abdominal abscesses and abdominal fluid
collections, American Society of Anesthesiologists (ASA)
III en IV, insufficient understanding of the Dutch lan-
guage or cognitively inability to complete Dutch ques-
tionnaires.
Participating centers
Twenty-seven centers will enroll patients. Five of these
hospitals are academic hospitals.
Ethics
The study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The protocol has been approved by the Medi-
cal Ethical Committee of the Academic Medical Center in
Amsterdam and the local Ethical Committees of the par-
ticipating centers. Prior to randomization informed con-
sent will be obtained from patients.
Study Outline
Recruitment
Patients will be recruited in the outpatients IBD clinics of
the participating medical centers. Patients may not want
to participate in the study because they reject the principle
of randomization, especially since the randomization of
this trial will result in two very divergent treatment strate-
gies. A small pilot study in the AMC IBD clinic learned
that most patients would participate as long as careful and
clear explanation of the study is offered. In a prior study
comparing laparoscopic with open ileocolic resection per-
formed by our institute only 2 out of 62 patient refused
participation or randomization [14].
Infliximab
Patients randomly allocated to infliximab treatment arm
will undergo remission induction consisting of three sub-
sequent infusions at week 0, 2 and 6 in a dose of 5 mg/kg.
Infliximab maintenance therapy, consisting of infusions
of 5 mg/kg at 8 to 12 weeks intervals, will be given to
patients with active disease after an episode of disease
activity that was treated with infliximab remission induc-
tion. In case of disease recurrence during infliximab treat-
ment intervals will be shortened to 6 weeks and/or the
dose level increased to 10 mg/kg. Infusion reactions will
be treated with 25 mg prednisolone and 2 mg clemastine
intravenously prior to subsequent infusions. Infliximab
therapy will be combined with azathioprine immu-
nomodulation in a dose of 2,5 mg/kg daily or 6-mercap-
topurine 1,5 mg/kg daily. In the case of intolerance to
these immunomodulating agents methotrexate will be
given in an intramuscular dose of 15 mg once a week. Inf-
liximab will be given without any co-medication in case of
intolerance to abovementioned immunomodulating
drugs or in case of contra-indications for the use of these
drugs. Patients total blood counts and liver enzymes will
be monitored 2 and 4 weeks after initiation of therapy and
subsequently at 3 months intervals.
(Laparoscopic) ileocolic resection
Patients randomly allocated to surgery receive a short
course of steroids to reduce the inflammation, consisting
of prednisolone 40 mg oral dose (OD) for one week, 30
mg OD during one week, 20 mg OD for 1 week, followed
by a dose of 10 mg. Once steroid therapy has been tapered
to a dose of 20 mg/day ileocolic resection can be per-
formed.
Surgery will be performed under general anesthesia.
Patients will receive antibiotics for 24 hours. Ileocolic
resection is done preferably laparoscopically. A variety of
techniques can be applied performing a laparoscopic ile-
ocolic resection ranging from a facilitated (laparoscopic
mobilization of the right colon followed by extracorpor-
eal vascular ligation, bowel transsection and reanastomo-
sing) to a total laparoscopic procedure (all steps are done
intracorporeally including anastomosis making). Gener-
ally, 3 or 4 trocarts suffice. The minilaparotomy preferably
is done as an up and down transumbilical incision or in
case of a large specimen as a Pfannenstiehl incision.
Statistical analysis
Intention to treat
The analysis will be performed in accordance with the
intention to treat principle.
Sample size calculation
The primary outcome of the study is a difference in IBDQ
total score between the two randomized groups at one
year. In order to assess the sample size for this study, a 0.5
between-group effect size on the IBDQ total score at week
48 was considered to be relevant. A modest effect size of
0.50 is generally considered to be clinically relevant. WithBMC Surgery 2008, 8:15 http://www.biomedcentral.com/1471-2482/8/15
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a 5% two-sided significance level, 65 patients per study
arm will be needed to achieve an 80% power to detect
such a difference with a two-sided t-test [21]. Additional
mixed-models repeated measures analysis of variance will
be used to investigate whether there is a different pattern
of change over time between the two study arms in the
four IBDQ dimensions and the EQ 5D [22].
Data collection and monitoring
Patients will be followed for a period of 12 months. Seven
times during this follow-up period patients will complete
a set of questionnaires (the IBDQ, EQ 5D, SF-36 and
BIQ): patients will complete the first set of questionnaires
before randomization, the next set at week 2 of their ther-
apy, the third set at week 6 and after that every 3 months
(3, 6, 9 and 12 months after start of therapy). The ques-
tionnaires will be sent to the patients by post accompa-
nied by a return envelop provided with postage stamps
and the address of the hospital. Collection of the ques-
tionnaires will be safeguarded by the trial coordinator.
Additional to the questionnaires, disease activity will be
assessed by calculating the CDAI. For this calculation
patients will be asked to keep a diary for seven days. In
total, patients will fill in 7 diaries. During a visit to the gas-
tro-enterologist or trial-nurse, hematocrit, presence or
absence of an abdominal mass and number of complica-
tions will be assessed. CDAI can be calculated from these
data combined with data from the CDAI-diaries. These
visits will coincide with visits to the outpatient depart-
ment for conventional patient care. At the end of the study
period, after 12 months, patients will undergo an endos-
copy to measure the extent of inflammation 12 months
after therapy. Patients that received an ileocolic resection
will be scored using the Rutgeerts endoscopic score.
Patients will be contacted by telephone every month by a
trial nurse to assess complications, additional interven-
tions, re-admissions, duration of hospital and intensive
care stay and visits to the outpatient clinic, number of
days of sick leave and of social in attendance and to ensure
completions of the questionnaires.
An electronic Case Record Form (CRF) will include gen-
eral patient's data (sex, age, medical history etc), patient's
response to the questionnaires and data concerning type
of intervention, complications, mortality, duration of
hospital and intensive care stay.
An independent trial monitor from the IBD trial-depart-
ment will monitor the study procedure and the data of
included patients.
Data analysis
As we do not expect a difference in mortality, data on
quality of life will be the key outcome measure in the
comparison. Differences in quality of life and morbidity
will be analyzed using mixed-models analysis of variance
for repeated measures, accounting for differences in sur-
vival between groups. Mortality will be compared using
Kaplan-Meier curves and log-rank statistics.
To analyze the secondary outcomes (general quality of
life, number of days on sick leave, morbidity (due to
either surgery or medical treatment) and results of the
body image questionnaire) the two groups will be com-
pared using the statistical program SPSS 14.0®.
A data and safety monitoring committee will safeguard
trial continuation based on safety and effectiveness data.
They will perform an interim analysis after 60 included
patients have reached a one month follow up.
Economic evaluation
The marginal direct medical, non-medical and time cost,
costs per QALY and cost-utility ratio will be calculated for
the surgical and medical treatment strategies. Cost items
will include costs of hospital admissions and readmis-
sions (operation, nursing days, outpatient visits), institu-
tional care (nursing homes, hospice), home care,
medication and other health care providers as well as
direct non-medical costs (travel expenses). Costs will be
calculated by counting resource use in the diaries, ques-
tionnaires and additional 3 month interviews and multi-
plying these with unit prices. Standard unit prices will be
used when available, complemented by results from cost
calculations where needed.
The cumulative total costs will be calculated for the 12
month study period. In addition, the cumulative costs for
each cost category will be calculated.
The EQ-5D score profiles will be transposed to health util-
ity values following scoring algorithms based on time
trade-off elicitation techniques applied in the general
population. Both the UK and the Dutch scoring algo-
rithms will be applied and compared in sensitivity analy-
ses. QALY's are calculated as the product-sum of health
utilities and the lengths of the preceding period in-
between measurements during follow-up. In the final
analysis, a 12 month difference in average QALY's will be
calculated.
Discussion
In the Netherlands infliximab treatment is indicated for
patients with Crohn's disease that are either steroid refrac-
tory or steroid dependent following treatment with ster-
oids alone or in combination with immunomodulatory
drugs such as azathioprine or methotrexate [23]. These
guidelines are in concert with the European consensus on
infliximab treatment [4]. However, the ECCO also recom-
mends in its consensus statement the need for trials com-BMC Surgery 2008, 8:15 http://www.biomedcentral.com/1471-2482/8/15
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paring infliximab and surgery stating that 'infliximab
should be considered for steroid or immunomodulatory
disease or intolerance, although surgical options should
be considered and discussed.' The LIR!C-trial aims to
diminish this discussion and to provide an evidence-
based best treatment strategy.
Besides infliximab (Remicade®), new biologic agents have
been introduced in the past few years. Adalimumab
(Humira®), a human anti-TNF monoclonal antibody, has
possible advantages over infliximab in administration
route and costs. In the future, therefore, adalimumab
might become the preferred biological treatment. Never-
theless, at this moment adalimumab as therapy for
Crohn's disease is relatively young and still proving itself.
Four placebo-controlled trials assessing efficacy in
Crohn's disease have been conducted so far, analyzing
1400 patients. Conclusions were that adalimumab is
more effective than placebo for remission-induction and
maintaining remission [24-27]. No trials comparing adal-
imumab and infliximab head to head have been pub-
lished yet. Because of lack of sufficient long-term data we
chose to not use adalimumab in this study. Certoluzimab
Pegol (Cimzia®), a polyethylene glycolated anti-TNFα
antibody fragment was associated with a modest improve-
ment in response rates but with no significant improve-
ments in remission rates if compared to placebo [28]. As
maintenance therapy outcomes on response and remis-
sion were better compared to placebo-therapy [29]. How-
ever, it has not been registered in Europe yet for the
therapy of Crohn's disease and therefore it is not included
in this trial either.
This trial compares medical therapy with (minimal inva-
sive) surgery for Crohn's disease of the distal ileum. The
first analysis will provide short- and medium-term results
up to one year of follow-up. However, since long-term
data of this cohort are especially of importance, we aim to
develop a follow-up study to continue follow-up after the
first year.
Considering the drawbacks of infliximab treatment, ileo-
colic resection can be an equivalent alternative treatment,
in spite of a small risk on serious surgical complications.
Both strategies have not been compared in a clinical trial
so far [4]. Infliximab treatment may be less cost-effective
when compared to laparoscopic ileocolic resection and
may show less effective when assessed by means of quality
of life. Therefore this study aims to answer the question
which treatment is to be preferred for recurrent distal ilei-
tis: medical therapy or early surgery.
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